Shonali Midha, M.D.

Myeloma Clinical Investigator @DanaFarber @harvardmed via @MoffittNews USF Heme/onc, @NorthwesternU BME, Baker, Jersey girl. Views = my own, not employer

[nizar jacques bahlis @NBahlis]

My summary of CARTITUDE4, MajesTEC3, MajesTEC9 and MoumenTAL3. In anti-CD38 refractory patients and EMDs -->TCE anti-BCMA or anti-GPRC5D are >> to Cilta-Cel

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

History in action here at #EHA2026!

Such impressive PFS & OS with a BCMA-sparing #downwithdex regimen in myeloma... a few of my own patients are on these K-M curves and doing great.

Tal-Dara ± pom (adding pom: more neutropenia/fatigue but ❓ slightly higher PFS) coming soon!

[Andrew Portuguese, MD @AJPortuguese]

📄1/ Our multicenter real-world study of elranatamab in relapsed/refractory multiple myeloma is out today in @BloodCancerJnl.

The main finding: outcomes in routine practice were meaningfully less favorable than those reported in MagnetisMM-3 cohort A.

https://t.co/nslRx16ywj

[Muzaffar Qazilbash @Transplant_Doc]

Anti-CD70 CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Potential future role in MM relapsing after anti-BCMA Rx #mmsm #bmtsm @MDAndersonNews @lab_rezvani @BCD_AACR https://t.co/3GRLvRA1TZ

[Dana-Farber @DanaFarber]

We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: https://t.co/BMbN681I8i

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd
- Update: 11/19/25 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd - Update: 11/12/25 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan

[Taxiarchis Kourelis @Taxkourel]

📊 My favorite #ASH2025 abstracts on #MultipleMyeloma and #Amyloidosis. Do not mention lots of trials and heavy on amyloid. @mtmdphd

[Robin Tuohy @IMFsupport]

How grateful are we in the #myeloma coMMunity to have dedicated and caring specialists spend their Saturday to present to patients and care partners?! @andrew02114 @ShoMidha @IMFmyeloma Regional Community Workshop in Waltham, MA #KnowMyeloma

[Francesco Maura @FrancescoMaura4]

Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ Our call to action is out in @BloodAdvances!

Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold.

Global authors & global audience, including insurance & healthcare funders.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Thanks @VuMedi for featuring our @BloodAdvances piece around driving restrictions following CAR-T therapy in MM.

Driving cars after CARs: an easy Twitter pun but a fundamentally important issue for pts. Data don't support 8-week driving restrictions!

https://t.co/sSDE9jM3tv

[Shonali Midha, M.D. @ShoMidha]

@JoannaBlocka @frede_julia @marius_mathies @NikhilMunshiMD @andrew02114 @dfg_public Very well deserved and so happy to collaborate!

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 25, 2024 - cc @grpetersen1 - @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @szusmani et al.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Single-cell analysis of myeloma TME after gamma-secretase inhibition & CAR T therapy finds reduction in non-classical monocytes & monoallelic BCMA deletion in some pts w/ prior anti-BCMA which correlated w/ reduced PFS: https://t.co/RVnKmnV5m5. #mmsm

[Anirban Maitra @Aiims1742]

Four institutions join together to form Cancer AI Alliance
@fredhutch @JohnsHopkins @DanaFarber @MSKCancerCenter
https://t.co/9edvIAMgSA

[ASH @ASH_hematology]

New: cilta-cel, a #CART for multiple myeloma, found highly effective in first real-world study.

Read more from @SurbhiSidanaMD and colleagues today in @BloodJournal: https://t.co/suFaGSSOoS #mmsm #Cartitude

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

@RahulBanerjeeMD @SurbhiSidanaMD @BloodJournal @DrKrinaPatel @Radhika_Bansl @ShoMidha @bhemato @DimaDanai @freemanlciaraMD @YiLinMDPhD @JanakiramMurali @khouri_jack @TomBmt133 Fascinating data. The major question is now long-term toxicities that we must continue to monitor. If MNT can be kept low, will be a major step forward. Will be interesting to see SPMs when used in earlier lines Critical publication. My mind map below:
#mmsm

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Congrats @SurbhiSidanaMD and whole #MMsm Consortium on newest @BloodJournal paper!

RW cilta-cel CAR-T outcomes (n >200). Largely CART-1 ineligible, but pts overall did well.

Among BCMA-exposed, ≥6 month washout reasonable pending better diagnostics.

https://t.co/aYR42vAddx

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Pre-clinical in vitro data suggest CD38/CD3xCD28 trispecific T-cell engager (SAR442257) may work in patients after prior daratumumab: https://t.co/ckst0KO7It. Interestingly, TCE lacking CD38-binding also worked, suggesting CD28 binding is enough. #mmsm